Who is Pitobrutinib/Pitobrutinib suitable for?

Pirtobrutinib/Jepali (Pirtobrutinib) is a new type of BTK inhibitor that has attracted much attention in the field of hematological tumors in recent years. Unlike early Bruton's tyrosine kinase (BTK) inhibitors, it is a non-covalent, reversibly binding inhibitor that can continue to work when patients develop resistance or intolerance to traditional BTK inhibitors. Therefore, it shows important value in patients with relapsed or refractory lymphoma who have limited treatment options.

From the perspective of the applicable population, pitubrutinib is mainly used for two types of patients. The first category is adult patients with relapsed or refractory mantle cell lymphoma (MCL), provided that these patients have received at least two systemic treatment regimens, which must include a BTK inhibitor. Mantle cell lymphoma is an aggressive non-Hodgkin lymphoma that often relapses after initial treatment, has limited subsequent treatment options, and has a poor prognosis. Pitobrutinib provides new treatment opportunities for these patients, especially when conventional BTK inhibitors have failed and can still exert anti-tumor effects.

The second category is chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Adult patients also need to meet the conditions of having received at least two lines of treatment, and the previous treatment includes BTK inhibitors and BCL-2 inhibitors. Such patients often have experienced multiple rounds of treatment, have difficult disease control, are highly resistant to treatment, and have limited efficacy with traditional drugs. Pitobrutinib, with its unique mechanism of action, has outstanding advantages in filling this treatment gap.

Compared with early covalent BTK inhibitors (such as ibrutinib, acotinib, etc.), pitubrutinib has stronger inhibitory ability against mutation-resistant strains, a relatively lower incidence of adverse reactions, and better long-term tolerance. Therefore, it is particularly suitable for patients whose disease has progressed after treatment with BTK inhibitors or who are unable to continue treatment due to side effects.

Reference materials:https://go.drugbank.com/drugs/DB17472